125 related articles for article (PubMed ID: 38706390)
1. Efficacy of ferric carboxymaltose on haemoglobin response among older patients with gastrointestinal bleeding: a randomised clinical trial.
Richard N; Arab-Hocine N; Vannier M; Leblanc-Boubchir R; Pelaquier A; Boruchowicz A; Musikas M; Amil M; Fumery M; Nahon S; Arotcarena R; Gelsi E; Maurin A; Hébuterne X; Savoye G
Age Ageing; 2024 May; 53(5):. PubMed ID: 38706390
[TBL] [Abstract][Full Text] [Related]
2. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial.
Kim YW; Bae JM; Park YK; Yang HK; Yu W; Yook JH; Noh SH; Han M; Ryu KW; Sohn TS; Lee HJ; Kwon OK; Ryu SY; Lee JH; Kim S; Yoon HM; Eom BW; Choi MG; Kim BS; Jeong O; Suh YS; Yoo MW; Lee IS; Jung MR; An JY; Kim HI; Kim Y; Yang H; Nam BH;
JAMA; 2017 May; 317(20):2097-2104. PubMed ID: 28535237
[TBL] [Abstract][Full Text] [Related]
3. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
4. Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia.
Mishra V; Gandhi K; Roy P; Hokabaj S; Shah KN
J Nepal Health Res Counc; 2017 Sep; 15(2):96-99. PubMed ID: 29016575
[TBL] [Abstract][Full Text] [Related]
5. Interventions for treating iron deficiency anaemia in inflammatory bowel disease.
Gordon M; Sinopoulou V; Iheozor-Ejiofor Z; Iqbal T; Allen P; Hoque S; Engineer J; Akobeng AK
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013529. PubMed ID: 33471939
[TBL] [Abstract][Full Text] [Related]
6. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with ferric carboxymaltose in the management of anemia in acute gastrointestinal bleeding.
Ballester-Clau R; Torres Vicente G; Voltà-Pardo T; López-Barroso L; Cucala-Ramos M; Reñé-Espinet JM; Planella de Rubinat M
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):116-122. PubMed ID: 30335628
[TBL] [Abstract][Full Text] [Related]
8. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
[TBL] [Abstract][Full Text] [Related]
9. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.
Khalafallah AA; Yan C; Al-Badri R; Robinson E; Kirkby BE; Ingram E; Gray Z; Khelgi V; Robertson IK; Kirkby BP
Lancet Haematol; 2016 Sep; 3(9):e415-25. PubMed ID: 27570088
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial.
Vanobberghen F; Lweno O; Kuemmerle A; Mwebi KD; Asilia P; Issa A; Simon B; Mswata S; Schmidlin S; Glass TR; Abdulla S; Daubenberger C; Tanner M; Meyer-Monard S
Lancet Glob Health; 2021 Feb; 9(2):e189-e198. PubMed ID: 33245866
[TBL] [Abstract][Full Text] [Related]
11. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding.
Mahey R; Kriplani A; Mogili KD; Bhatla N; Kachhawa G; Saxena R
Int J Gynaecol Obstet; 2016 Apr; 133(1):43-8. PubMed ID: 26868063
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.
Covic A; Mircescu G
Nephrol Dial Transplant; 2010 Aug; 25(8):2722-30. PubMed ID: 20190247
[TBL] [Abstract][Full Text] [Related]
14. FAIRY: a randomized controlled patient-blind phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject®) to placebo in patients with acute isovolemic anemia after gastrectomy - study protocol for a randomized controlled trial.
Reim D; Kim YW; Nam BH; Kim MJ; Yook JH; Park YK; Roh SH; Yu WS; Bae JM
Trials; 2014 Apr; 15():111. PubMed ID: 24708660
[TBL] [Abstract][Full Text] [Related]
15. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
Stein J; Aksan A; Klemm W; Nip K; Weber-Mangal S; Dignass A
J Crohns Colitis; 2018 Jun; 12(7):826-834. PubMed ID: 29955835
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831
[TBL] [Abstract][Full Text] [Related]
18. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of intravenous ferric carboxymaltose in improving hemoglobin level among postpartum women with moderate-to-severe anemia at a secondary care hospital in Faridabad, Haryana - An interventional study.
Kant S; Kaur R; Ahamed F; Singh A; Malhotra S; Kumar R
Indian J Public Health; 2020; 64(2):168-172. PubMed ID: 32584300
[TBL] [Abstract][Full Text] [Related]
20. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
